Evidence map›Paper›PMID 32104382›Full record

ArticleAsian journal of pharmaceutical sciences2018

Pulmonary delivery of liposomal dry powder inhaler formulation for effective treatment of idiopathic pulmonary fibrosis.

S Chennakesavulu, A Mishra, A Sudheer, C Sowmya, C Suryaprakash Reddy, E Bhargav

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian journal of pharmaceutical sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 79 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

S ChennakesavuluPharmacy Department, NDDS Laboratory, Donors Plaza, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Gujarat, India.
A MishraPharmacy Department, NDDS Laboratory, Donors Plaza, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Gujarat, India.
A SudheerPharmacology Department, Faculty of Technology and Engineering, The Maharaja Sayajirao University of Baroda, Gujarat, India.
C SowmyaCenter for Pharmaceutical Research, Pharmaceutics Department, Raghavendra Institute of Pharmaceutical Education and Research, Anantapuramu 515721, Andhra Pradesh, India.
C Suryaprakash ReddyCenter for Pharmaceutical Research, Pharmaceutics Department, Raghavendra Institute of Pharmaceutical Education and Research, Anantapuramu 515721, Andhra Pradesh, India.
E BhargavCenter for Pharmaceutical Research, Pharmaceutics Department, Raghavendra Institute of Pharmaceutical Education and Research, Anantapuramu 515721, Andhra Pradesh, India.
Maharaja Sayajirao University of Baroda · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dry powder inhaler Liposomes were prepared to investigate the effectiveness of pulmonary delivery of Colchicine and Budesonide for Idiopathic Pulmonary fibrosis. Budesonide (BUD) and Colchicine (COL) liposomes were prepared by thin layer film hydration method (TFH) using 1,2-Dipalmitoyl-sn-glycero-3- phosphoglycerol sodium (DPPG), Hydrogenated Soyaphosphotidylcholine (HSPC), Soyaphosphatidylcholine (SPC), cholesterol (CHOL) and drug in different weight ratios. The optimum lipid composition for BUD (74.22 ± 0.97%) was DPPG: HSPC: CHOL (4:5:1) and for COL (50.94 ± 2.04%) was DPPG: SPC: CHOL (3:6:1). These compositions retained drug for a longer period of time so selected for further study. Liposomes were found to be spherical in shape with mean size below 100 nm. Liposomes lyophilized using Mannitol as carrier and cryoprotectant showed high entrapment efficiency (97.89 - 98.6%). The powder was dispersed through an Andersen cascade impactor to evaluate the performance of the aerosolized powder. It was found that prepared liposomal dry powder inhaler (DPIs) sustained the drug release up to 24 hours. Optimized Budesonide DPI Formulation B2 (86.53 ± 1.9%), Colchicine DPI Formulation C2 (90.54 ± 2.3 %) and BUD and COL DPI Combination M2 (89.91 ± 1.8%, 91.23 ± 1.9%). Histopathological results, measurements of lung hydroxyproline content, Myeloperoxidase activity indicated that liposomal dry powder inhaler administration attenuates lung fibrosis induced by bleomycin. Long term stability studies indicated that lyophilised BUD and COL liposomes were stable for 6 months at (25 °C ± 2 °C, 60% ± 5% RH) and refrigerated conditions (2 - 8 °C). These results supported that combination of budesonide and colchicine liposomal dry powder inhaler pulmonary drug delivery for treatment of idiopathic Pulmonary Fibrosis exhibits prolonged drug retention at targeted site and reduces the systemic exposure.

Indexed as

BLM, BleomycinBudesonideColchicineDE, Drug entrapmentDPI, Dry Powder InhalerEPC, Egg phosphatidyl cholineFPF, Fine particle fractionHDPE, High density polyethyleneIdiopathic Pulmonary fibrosisLiposomal dry powder inhalerM2, Mixture of BUD & COL (Optimized formulation)MDI's, Metered Dose InhalersMMAD, Mean Median Aerodynamic diameterPBS, Saline Phosphate bufferPulmonary drug deliveryPVC, Poly vinyl chlorideSLS, Sodium lauryl sulphateUV, Ultraviolet

Identifiers

PMID32104382
PMCPMC7032187
OpenAlexW2750252889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.